Needham & Company LLC Issues Positive Forecast for NeoGenomics (NASDAQ:NEO) Stock Price

NeoGenomics (NASDAQ:NEO) had its price objective boosted by Needham & Company LLC from $19.00 to $22.00 in a report released on Tuesday morning, MarketBeat Ratings reports. The firm currently has a buy rating on the medical research company’s stock.

A number of other equities analysts also recently issued reports on NEO. Benchmark increased their price target on NeoGenomics from $11.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Zacks Research cut NeoGenomics from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Wall Street Zen raised NeoGenomics from a “hold” rating to a “buy” rating in a research note on Saturday, June 27th. Craig Hallum reiterated a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a research report on Wednesday, July 29th. Finally, Weiss Ratings raised shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, NeoGenomics presently has a consensus rating of “Moderate Buy” and an average target price of $18.17.

NeoGenomics Stock Performance

NEO opened at $16.50 on Tuesday. The firm has a fifty day moving average price of $17.46 and a 200 day moving average price of $12.94. The stock has a market cap of $2.12 billion, a P/E ratio of -41.25 and a beta of 1.79. NeoGenomics has a 1 year low of $7.07 and a 1 year high of $20.15. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.60 and a quick ratio of 3.35.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, July 28th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.02. NeoGenomics had a negative net margin of 6.77% and a negative return on equity of 1.99%. The business had revenue of $201.66 million for the quarter, compared to analyst estimates of $196.93 million. During the same period in the prior year, the company posted $0.03 EPS. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. Equities research analysts anticipate that NeoGenomics will post -0.09 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Allworth Financial LP increased its stake in NeoGenomics by 110.4% during the 2nd quarter. Allworth Financial LP now owns 4,132 shares of the medical research company’s stock worth $60,000 after buying an additional 2,168 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of NeoGenomics in the second quarter valued at approximately $99,000. MQS Management LLC purchased a new position in shares of NeoGenomics in the first quarter valued at approximately $75,000. Stephens Inc. AR acquired a new stake in shares of NeoGenomics in the first quarter worth approximately $143,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of NeoGenomics in the second quarter worth approximately $296,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

NeoGenomics News Roundup

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: NeoGenomics projected third-quarter 2026 revenue of $209 million, above the $205.8 million analyst consensus. Full-year revenue guidance of $802 million to $806 million was broadly in line with the $803.8 million consensus, supporting expectations for continued growth. NeoGenomics Names Warren Stone as Next CEO; Reports Q3 Revenue Guidance
• Positive Sentiment: Needham raised its price target for NeoGenomics (NEO) to $22 from $19 and maintained a Buy rating, implying meaningful upside based on the referenced share price. The broader analyst view was characterized as a Moderate Buy. Needham Raises NeoGenomics Price Target
• Neutral Sentiment: The company announced that Warren Stone will become its next chief executive and outlined executive and board succession changes, with board changes effective January 4, 2027. The plan may provide continuity, but investors are assessing how the transition could affect strategy and execution. NeoGenomics Announces Executive Leadership and Board Succession Plan
• Negative Sentiment: The leadership change overshadowed the favorable outlook, causing the stock to fall as investors reacted to CEO succession uncertainty. Coverage specifically described the decline as occurring despite the revenue beat and strong third-quarter outlook. NeoGenomics Sinks on CEO Succession Plan Despite Revenue Beat

About NeoGenomics

NeoGenomics, Inc (NASDAQ:NEO) is a specialized oncology diagnostics company that provides testing services to hospitals, physicians, pathologists, pharmaceutical companies and other healthcare organizations. Its services support the diagnosis, classification and monitoring of cancer, helping guide treatment decisions and drug development.

The company offers a broad range of pathology and laboratory services, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, cytogenetics, flow cytometry, immunohistochemistry and digital pathology.